Prestige Biopharma and Biosidus Forge Strategic Alliance
SINGAPORE — Prestige Biopharma, a forward-thinking biopharmaceutical entity focusing on antibody therapies, has recently collaborated with Biosidus, an established biotechnology firm based in Argentina. This partnership comes with an exclusive licensing and supply agreement aimed at promoting Tuznue® (trastuzumab) throughout various Latin American countries.
About Tuznue® and Its Significance
Tuznue® serves as a biosimilar to Herceptin® (trastuzumab), a well-known medication utilized in the management of breast cancer and metastatic gastric cancer. In a significant step for the company, Prestige Biopharma obtained marketing approval from the European Commission for Tuznue® in September 2024. This pivotal approval signifies not just an achievement for the firm but also a broader movement toward making affordable treatment options available on a global scale.
Exclusive Marketing Rights Granted to Biosidus
Under the terms of their agreement, Biosidus has obtained the exclusive rights to distribute and market Tuznue® in key markets, including Argentina, Mexico, Bolivia, and Paraguay. Their extensive commercial connections and expertise in biosimilar integration position them as a suitable partner for this venture. Meanwhile, Prestige Biopharma will handle the production and supply of the drug from its top-notch, EU-GMP-certified manufacturing facility.
Statements from Leadership
Lisa S. Park, CEO of Prestige Biopharma, expressed enthusiasm about the collaboration: "This strategic partnership with Biosidus empowers us to further our mission in Argentina and other vital Latin American markets. We believe that with their strong regional foothold, we can effectively introduce our leading biosimilar to the healthcare community."
Mariano Elizalde, CEO of Biosidus, also shared his excitement: "Working together with Prestige Biopharma allows us to boost our portfolio of biosimilars and underlines our dedication to providing biotech medicines across Latin America. Our collaboration opens new possibilities for patients and healthcare providers alike, establishing Tuznue® as a viable option."
Understanding Tuznue® in More Detail
Tuznue® stands out as a cost-efficient alternative to the brand-name Herceptin® (trastuzumab), offering similar effectiveness and safety standards. It caters to patients suffering from conditions like HER2-positive metastatic breast cancer and HER2-positive gastric cancer, thereby expanding treatment accessibility.
A Closer Look at Prestige Biopharma
Founded in 2015, Prestige Biopharma has carved a niche for itself in the biopharmaceutical industry. The company boasts a wide-ranging product lineup that includes pioneering antibody medications and various vital biosimilars currently undergoing clinical evaluation. One prominent candidate is ulenistamab, a next-generation antibody treatment that has received numerous designations to facilitate its progress through clinical phases.
About Biosidus and Its Legacy
Biosidus has a remarkable legacy, being a trailblazer in the biotechnology sector for over 42 years. It has successfully established a strong presence in Latin America and is increasingly recognized in emerging markets such as Asia and Africa. Their commitment lies in delivering high-quality biopharmaceutical products at competitive prices to elevate healthcare standards in their regions.
Frequently Asked Questions
What is the significance of the Tuznue® agreement?
The agreement allows for the effective commercialization of Tuznue® across Latin America, increasing access to treatment for patients.
Who is Prestige Biopharma?
Prestige Biopharma is a biopharmaceutical company focused on developing antibody therapeutics and biosimilars.
What is Tuznue®?
Tuznue® is a biosimilar to Herceptin® and is indicated for the treatment of certain types of breast and gastric cancers.
Where will Tuznue® be marketed?
Biosidus will market Tuznue® in Argentina, Mexico, Bolivia, and Paraguay.
What is the role of Biosidus in this partnership?
Biosidus will manage the marketing and distribution of Tuznue® while also manufacturing the drug for local and export markets.
